At the recent Bleeding Disorders Conference, an interactive pre-conference session on von Willebrand Disease (VWD) offered attendees a tantalizing look into the future of treatment and care. The session, sponsored by CSL Behring and led by Lena Volland, brought together experts, patients, and innovators to discuss groundbreaking initiatives and technologies.
Mark Skinner and Elizabeth Clearfield shared insights from the coreVWD initiative, a rigorous effort to identify treatment outcomes most important to patients. "One key takeaway is that both the length and volume of menstrual bleeding are critically important to lived experience experts when considering treatments," Clearfield noted. This patient-centric approach is set to influence future treatment development significantly.
Adding a personal touch, Matt Delaney and Jessica Graham shared their experiences as members of the coreVWD panel, bringing the patient perspective to the forefront of the discussion.
The session took an exciting turn with the introduction of FiveLiters, an innovative company in NBDF's Pathway to Cures portfolio. CEO Daniel Powell presented their non-invasive neurostimulation device, which shows promise in addressing unmet needs in the VWD community.
"Early clinical trials with type 1 VWD patients experiencing heavy menstrual bleeding have shown a 45% reduction in blood loss," Powell revealed, sharing data from the first five patients using the device. This breakthrough could potentially transform the lives of many living with VWD.
